12 Jan 2021
Pfizer-BioNTech leads the COVID-19 vaccine race with forecasted sales of $30 billion
By Staff Writer
Pfizer-BioNTech’s two-shot mRNA COVID-19 vaccine, BNT-162b2, is expected to be the fist globally available vaccine for COVID-19. It is currently the leading prophylactic vaccine for COVID-19 based on forecast sales, expected to generate $30 billion in sales from 2020 to 2026, with peak sales of $13.9bn in 2021, according to GlobalData. COVID-19 vaccines in demand...
